DaVita Inc. (NYSE:DVA) Receives $161.80 Consensus Target Price from Analysts

DaVita Inc. (NYSE:DVA) has been assigned a consensus rating of “Hold” from the five ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $161.80.

A number of equities research analysts recently weighed in on DVA shares. Barclays raised their target price on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Truist Financial lifted their price objective on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th.

DaVita Price Performance

DVA stock opened at $153.02 on Friday. DaVita has a 12 month low of $103.40 and a 12 month high of $169.51. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The firm has a market capitalization of $12.55 billion, a P/E ratio of 16.51, a price-to-earnings-growth ratio of 0.86 and a beta of 0.90. The firm has a 50 day moving average of $157.00 and a 200-day moving average of $150.97.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same period in the prior year, the business posted $2.85 EPS. DaVita’s quarterly revenue was up 4.6% on a year-over-year basis. As a group, sell-side analysts predict that DaVita will post 9.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DaVita

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Transcendent Capital Group LLC purchased a new stake in shares of DaVita in the 3rd quarter worth approximately $25,000. Blue Trust Inc. lifted its position in DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares during the period. Family Firm Inc. purchased a new stake in DaVita in the second quarter worth approximately $43,000. Quarry LP bought a new stake in DaVita in the 3rd quarter worth approximately $60,000. Finally, Point72 Hong Kong Ltd purchased a new stake in DaVita during the 2nd quarter valued at $68,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.